WATTLE HEALTH AUSTRALIA LIMITED (WHA)

name changed to Wellnex Life Limited

The company releases an Appendix 2A - Rights Issue Shortfall Shares.

The company releases an Appendix 2A - Rights Issue.

The company releases an application for quotation of securities - WHA.

Wellnex Life completes acquisition of Brand Solutions Australia and Pharma Solutions Australia businesses. ASX has provided conditional approval for reinstatement of securities to trading. Wellnex Life will commence trading next week under new issuer code WNX (subject to satisfaction of all ASX Reinstatement Conditions).

The company releases a supplementary prospectus.

Rights Issue closed on 21 June 2021 and successfully raised $1.32 million. Shortfall placement to raise up to $1.56 million, opening tomorrow. The Company will provide a further update to the market regarding status of reinstatement of its shares to trading on the ASX under ticker WNX.

Entitlement Offer (and all other Offers) closing on 21 June 2021. Wellnex Life to trade under the code WNX.

The company releases an Investor Presentation.

Entitlement Offer (and all other Offers) closing date extended to 21 June 2021. Wellnex Life to trade under the code WNX.

The company releases an updated notice of proposed issue of securities.

The company releases its Constitution.

The company releases the Results of its Meeting.

The company releases the Director's AGM Speech.

The company's $2.88 million non-renounceable rights issue opens today. The Rights Issue Prospectus and personalised Entitlement and Acceptance Form for the nonrenounceable rights issue announced on 13 May 2021 have been despatched to Eligible Shareholders today. Wattle Health is funded to complete the BSA transaction, with all monies raised to be used as working capital to accelerate growth. The Closing Date for the Rights Issue is 7 June 2021. The Company has also despatched a letter to ineligible shareholders today.

The company releases an addendum to its notice of meeting. The addendum reflects the following changes: revised resolution 3, reasons for revision to resolution 3, revised explanatory notes to resolution 3 and voting information.

The company releases a notice of Proposed issue of Securities - WHA.

The company releases a letter to its ineligible shareholders regarding a non-renounceable pro-rata entitlement offer of new fully paid ordinary shares in Wattle.

Wattle Health to raise up to $2.88 million via a 1:12 non-renounceable Rights Issue at $0.15 per share. Opportunity for shareholders to participate at the same price as previous institutional placement and Brand Solutions Australia (BSA) transaction. Wattle Health fully funded to execute BSA transaction, with funds raised under this offer to accelerate growth.

The company releases a prospectus for the following offers: entitlement offer, advisor offer, lender offer, placement offer, consideration offer, noteholder offer.

The company releases an Updated Investor Presentation.

The company's AGM will be held on 21 May 2021 at 10am.

The company releases an Investor Presentation.

The company releases an Appendix 4C and Quarterly Report for March 2021 Quarter.

The company has entered into a binding asset sale agreement to acquire the asseets of leading brand and distribution business Brand Solutions Australia and Pharma Solutions Australia. A name transition to Wellnex Life will be put to shareholder approval. Wattle Health will be hosting an investor briefing on Thursday 15 April at 1pm AEST where Executive Director, George Karafotias, will discuss the Proposed Transaction and provide a general investor update. Register here - https://wattlehealth.investorportal.com.au/investorbriefing/

The company releases its half year report with the following highlights: Profit before loss of non-controlling interest of $2.57 million, Revenue up 54.2% on Prior Corresponding Period, Loss of net cashflows from operations reduced by 67.5% on PCP and Sale of the Corio Bay Dairy Group assets for $13.5 million.

The company lodges its Appendix 4D and Half Year Accounts.

Wattle Health now owns 100% of organic skincare brand Little Innoscents. Little Innoscents sales, predominantly through Chemist Warehouse and API, up 28% to $682,000 ($530,000 pcp) for the twelve months to 31 December 2020. The Company has plans to extend Little Innoscents product line and leverage supply chain efficiencies.

The company releases a Form 484 - Cancellation of Loan Shares.

The company releases a Final share buy-back notice - Appendix 3F.

The company lodges its Appendix 4C and Quarterly Report.

The company releases a notice of Announcement of buy-back - Appendix 3C.

The company will cancel 13,437,500 fully paid ordinary shares that were issued in December 2017 to directors and employees pursuant to the Employee Share Loan Plan and Loan Agreement Terms. Wattle Health continues to see strong growth through its supply agreement with Chemist Warehouse and, as previously announced, it had secured distribution with Australian Pharmaceuticals Industries for both Uganic and Little Innoscents product lines with first orders received. The licensing agreement with Verdure Nutrition Supplements Trading continues to progress with the first order being shipped to the Middle East this month and the finalisation of an Arabic version of the Uganic product in preparation of the second and subsequent orders.

The company releases an Appendix 4G and Corporate Governance Statement.

The delay of the company's lodgement of its annual report for financial year 2020 was due to the uncertain nature of the Corio Bay Dairy Group administration process. Wattle Health subsequently released an ASX announcement in relation to a binding transaction for the disposal of the assets of CBDG.

The company lodges its Annual Report.

Maeil Dairies has purchased the assets of Corio Bay Dairy Group for A$13.5 million. Maeil committed to finalise the construction of the Spray Dryer. Disposal allows Wattle Health to focus on continued growth of its nutritional dairy range.

The company has secured ranging for both Uganic and Little Innoscents products with Australian Pharmaceuticals Industries. With the recent ranging in API, the Uganic range of infant formula will now be available through all 3 Australian major Pharmacy wholesalers API, Symbion and Sigma, whilst the Little Innoscents range will now be available through API and Symbion.

Verdure Nutrition Supplements Trading LLC have placed the first purchase order of $140,000 for Wattle Health's organic infant formula for delivery in December.

Wattle Health Australia Limited Signs Licensing Agreement with Verdure Nutrition Supplements Trading LLC for WHA's Organic Infant Formula Range for the Middle Eastern Market. Verdure will be Responsible for the Manufacture, Transport and Marketing of Uganic under License Agreement. First Delivery of Uganic to Commence in December 2020.

The company lodges its Appendix 4C and Quarterly Report.

WHA raises $3 million via convertible note financing and engagement of Reach Corporate as Corporate Adviser. The administrator has been working on a sale campaign of CBDG and the Board of Wattle Health has indicated to the administrator of its willingness to evaluate and assess any proposals put forward by interested parties with a view to realise the best outcome for Wattle Health shareholders. The company also advises of its expanded Uganic products in chemist warehouse.

The company lodges its Appendix 4E and Preliminary Results.

The company lodges its Preliminary Final Report.

Corio Bay Dairy Group is placed into Voluntary Administration. WHA is working with administrators to realise best outcome for shareholders.

The company lodges its Appendix 4C - Quarterly Report for June.

WHA is aware of an article published in the AFR today stating that the Tax Practitioners Board has deregistered the Company's former chairman Mr Peter Biantes. As announced to the ASX on 17 June 2020, Mr Biantes resigned, with immediate effect, from the Board of Wattle Health citing health reasons. The Board was not aware of any details in relation to this matter prior to today's media coverage.

The company releases an Appendix 2A.

Milk supply agreement between Organic Dairy Farmers of Australia and Corio Bay Dairy Group was terminated by CBDG due to ODFA entering voluntary administration thus triggering an insolvency event under the MSA. This allows CBDG to renegotiate a potential new milk supply agreement with ODFA.

S&P Dow Jones Indices Announces June 2020 Quarterly Rebalance of the S&P/ASX Indices. All Ordinaries "“ Effective at the Open on June 22, 2020 - Removal - Wattle Health Australia Limited.

The directors of Organic Dairy Farmers of Australia Limited had placed ODFA into voluntary administration on 15 May 2020, and that Mr Ivan Glavas of Worrells had been appointed as the administrator. The milk supply agreement between ODFA and Corio Bay Dairy Group remains legally binding. Furthermore, CBDG is now able to source additional fresh organic milk from external parties. CBDG continues to work with Shepparton Partners Collective who remain engaged to arrange up to $20 million of funding for CBDG. Wattle Health, Niche Dairy and SPC intend to proceed with CDBG subject to due diligence being completed by SPC on CBDG to its satisfaction, definitive legal documentation and regulatory and shareholder approvals being obtained by all parties. Wattle Health will retain its 45% shareholding in CBDG post the proposed transaction with SPC.

The company releases a notice of Proposed issue of Securities - WHA.

The company has reached agreement terms with Shepparton Partners Collective on a strategic relationship that will see SPC arranging up to $20m of debt for Wattle Health to complete construction of the Corio Bay Dairy Group spray dryer. SPC will be issued 30 million fully paid ordinary shares in Wattle Health upon first drawdown of the loan. The strategic partnership will be in the form of a 50/50 joint venture with SPC that will leverage products, new product development, marketing, sales and distribution capabilities from both companies.

The company lodges its Appendix 4C - Quarterly Report.

WHA completes an Institutional and Sophisticated Investor Placement to raise $4.86 million by the issue of 32.45 million shares at $0.15 per share. WHA has also entered into a conditional term sheet with Shepparton Partners Collective Limited, one of Australia's leading Food Groups, for a Joint Venture and Funding proposal to jointly manage and develop an expanded product portfolio and distribute products collectively, and for SPC to assist WHA in facilitating a loan of up to $20 million to enable the construction of the Spray Dryer at Corio Bay Dairy Group to be completed.

The company releases a notice of Proposed issue of Securities - WHA.

The company releases an Appendix 3G.

WHA tendered a new proposal to Mason to complete the B&P Transaction. The New Tender was very similar to the previous transaction, but also considered commercial factors that had changed due to the extreme volatility in financial markets. The New Tender was not accepted by Mason and thus WHA is unable to complete the B&P Transaction. The company will immediately cancel the rights issue offer. The company will now work with Computershare to refund all application monies to shareholders who subscribed under the Rights Issue as soon as possible. The company still retains its 5% shareholding in Blend and Pack and will continue to manufacture its products through this facility. Mason retains its 75% shareholding in Blend and Pack with the balance of 20% continuing to be held by the founders. Wattle Health has implemented appropriate business continuity planning processes and there has been no significant disruption to ongoing business activity. Wattle Health is complying with all requirements, and instituted protocols and practices in line with Government regulations and recommendations. To date, production and sales of its products remain unaffected by Covid-19 related issues. Wattle Health's organic infant formula range Uganic has been ranged across more than 400 Chemist Warehouse stores in Australia through March. Direct sales of both Uganic and our healthcare and skincare range Little Innoscents were ahead of forecast in March. Construction work at the Corio Bay Dairy Group facility in Geelong is continuing and remains on schedule to commence operations in July but construction and equipment supplies is of course subject to government policy on lockdowns and general disruptions caused by the impact of COVID-19.

The Company received a notice of termination from Mason Dairy Holdings Limited late Monday 9 March 2020 in relation to the revised Share Purchase Agreement entered into between WHA and Mason. The Revised SPA related to the proposed partial acquisition of the Blend & Pack packaging and canning facility. The reason for the termination was due to the Company unable to settle with Mason under the Revised SPA before the sunset date of 29 February 2020. The Board is currently working with all parties involved with a view to work out a solution for all stakeholders. In particular, the Company is continuing a dialogue with Mason to achieve a sensible commercial outcome.

The company lodges its Appendix 4D - Half Year Report and Accounts.

Pursuant to the rights issue prospectus dated 23 January 2020, the company received a total of $9,316,105 from existing eligible shareholders for the rights participation. The total shortfall amount is $15,683,895 based on minimum subscription amount of $25 million. The company has secured firm commitment from Xuan Khoa Pham for the participation of any shortfall available under the one for two non-renounceable rights issue offer at an issue price of $0.40 to raise at least $25 million and up to $39.7 million under the prospectus dated 23 January 2020. The investor has signed a written commitment to subscribe for any shortfall shares at the issue price of $0.40 per share available under the rights issue offer up to the minimum subscription of $25 million.

The company releases the Results of Meeting.

The company has secured firm commitment from Xuan Khoa Pham a high net worth investor for the participation of any shortfall available under the two for one non-renounceable rights issue offer at an issue price of $0.40 to raise at least $25 million and up to $39.7 million under the prospectus dated 23 January 2020. The investor has signed a written commitment to subscribe for any shortfall shares at the issue price of $0.40 per share available under the rights issue offer up to the minimum subscription of $25 million. The rights issue offer close date is 19 February 2020.

The company lodges its Appendix 4C - Quarterly Report.

A conference call has been arranged for shareholders, institutions and interested parties in Australia, New Zealand and internationally on Wednesday 29th January 2020 at 2pm AEDT. All guests within Australia: Dial In: 1800 179 061 Guest Code: 1888035#. All guests internationally: Dial In: The number that applies to their country listed below. Guest Code: 1888035#.

The company releases a letter to ineligible shareholders regarding the non-renounceable entitlement offer.

The company releases a letter to its optionholders regarding its non-renounceable rights issue offer, which is open to all eligible shareholders of the company who are on the share register as at 5.00pm AEDT on 30 January 2020 and who have a registered address in Australia and New Zealand.

The company releases an Investor Presentation.

The company issues a prospectus for a non-renounceable pro-rata rights issue to Eligible Shareholders of up to 99,303,174 million New Shares on the basis of 1 New Share for every 2 Shares held by Shareholders at the Record Date at an issue price of $0.40 per New Share to raise a minimum of $25 million and a maximum of $39.7 million before costs.

The company's EGM will be held at the offices of K&L Gates, Level 25, South Tower, 525 Collins Street, Melbourne, Victoria at 11.00 am on Monday 24 February 2020.

The company has launched a new non-renounceable pro-rata rights issue offer to eligible shareholders of up to 99,303,174 shares to fund the acquisition of Blend and Pack. New shares will be offered on the basis of one new share for every two held by eligible shareholders resident in Australia or New Zealand on the record date (namely 30 January 2020) at an offer price of AU$0.40 each, to raise a maximum of AU$39.7 million before costs (with a minimum capital raise of AU$25 million).

The company will start ranging WHA's Uganic's infant formula range and Little Innoscents organic skin care range across Chemist Warehouse's retail network in March 2020. The company has today issued 4,103,208 fully paid ordinary shares under the Chemist Warehouse agreement, with the second and third tranche share issues being subject to shareholder approval in the upcoming shareholder meeting.

Following the release of the revised terms of the B&P Transaction on 13 January 2020, the Company has instructed Computershare to refund all application monies subscribed for the Non-Renounceable Rights Issue Offer to raise a minimum of $55 million and up to $62 million on the basis of 4 New Shares for every 5 Shares held by Shareholders at the Record Date at an issue price of $0.40 per New Share under a prospectus dated 18 November 2019. Refunds are expected to be paid on or around Friday 24 January 2020, in accordance with the payment instructions recorded on the Company's share register. The Company will be launching a new rights issue offer with details to be included in a new prospectus.

The arrangement with Chemist Warehouse has been renegotiated to allow WHA's Uganic's infant formula range and the Little Innoscents organic skin care range to be ranged across CW's retail network commencing March 2020. The company and W have agreed to remove the previous conditions precedent of a minimum capital raise under the rights issue of AU$62 million. All other terms and conditions remaining the same as previously announced. The first tranche of shares will be issued to CW immediately in order to commence their long-term supply agreement.

Nouriz (Shanghai) Fine Food and WHA have signed a shareholder's agreement to form a 50/50 Australian Joint Venture company which follows on from the Collaboration Agreement. The newly registered JV company "Australife Co. Pty Ltd" will own the brands on behalf of the shareholders for the sale of a range of products into the world's largest infant formula and nutritional powder market, China. The first products under the jointly owned brands are expected to be sold shortly after the commencement of the Corio Bay Dairy Group spray drying facility in the second half of CY2020.

Mason Group Holdings and Mason Dairy Holdings have signed a deed of amendment and restatement amending the share purchase agreement dated 14 November 2019, whereby the company would effectively acquire 75% of Blend and Pack, taking the company's interest in B&P to 80%. The proposed transaction is subject to shareholder approval and must be settled by no later than 29 February 2020. If shareholder approval is not obtained, or completion does not occur for any other reason, then subject to some exceptions the US$1 million deposit already paid will be forfeited and the company will be obliged to issue Mason a US$7.5 million worth of WHA shares. The company proposes to update the terms of the existing rights issue to reflect a new minimum capital raising and to incorporate the new terms for the revised Blend & Pack acquisition.

The company and Mason are continuing negotiations of a revised structure of the proposal to acquire 75% of the shares in Blend and Pack. The company's shares will remain in voluntary suspension pending a further update.

The company received a total of $11,670,447.20 from existing eligible shareholders via the company's share registry Computershare. The total shortfall amount is $50,570,322.40. The rights issue was partially underwritten for $20 million. The company received interest from potential investors in addition to the $11.6 million application from existing shareholders. However, the company was unable to secure the full amount of $55 million funding, required as the minimum offer amount under the prospectus. As a result of this, the underwriting agreement with Claymore Capital Pty Ltd lapsed on the 31 December 2019.

The company releases the results of its meeting.

The company issues a supplementary prospectus.

Wattle Health Australia Limited signs long term supply agreement with Chemist Warehouse for its Uganic range of certified organic nutritional dairy products and Little Innoscents organic skin care range. Chemist Warehouse to receive equity in WHA for marketing support and ranging across the Chemist Warehouse retail network including China and online. Chemist Warehouse is the largest pharmacy retailer in Australia with the largest presence in online sales in China via Tmall (a subsidiary of Alibaba) and the largest infant formula retailer in Australia.

The company releases the results of its meeting.

The company releases its AGM CEO Speech.

In light of the material uncertainties of both (i) WHA shareholder approval on 16 December 2019; and (ii) raising the minimum amount of $55 million under the rights issue; and also having regard to the potentially transformative nature of the combined transactions, WHA requested that the suspension from trading in the company's shares continue until immediately after the WHA shareholder meeting on 16 December 2019.

The company's extraordinary general meeting will be held at the offices of K&L Gates, Level 25, North Tower, 525 Collins Street, Melbourne, Victoria at 10.30am on 16 December 2019.

The company releases separate letters to its eligible shareholders, ineligible shareholders and optionholders regarding its rights issue offer.

The company issues a prospectus for a non-renounceable pro rata rights issue to eligible shareholders of up to 155,602,512 new shares on the basis of 4 new shares for every 5 shares held by shareholders at the record date at an issue price of $0.40 per new share to raise a minimum of $55 million and a maximum of approximately $62.2 million before costs.

The company releases an Investor Presentation.

The company has entered into a new agreement to acquire an additional 75% of CNCA accredited nutritional dairy manufacturing facility, Blend and Pack for an upfront payment of US$30 million and a deferred payment of US$25 million. WHA has launched a 4 for 5 non-renounceable rights issue at $0.40 per share to fund the initial payment to acquire B&P. The construction by Corio Bay Dairy Group of Australia's first dedicated organic nutritional dairy spray dryer is successfully progressing under budget, with planned completion and commissioning expected in the first half of CY2020.

The company has signed a collaboration agreement with Nouriz Fine Food. Nouriz sells its branded nutritional products via extensive distribution channels within China. Under the agreement, Nouriz and WHA will develop a 50/50 joint venture for the sale of Australian organic nutritional products sourced from the Corio Bay Dairy Group. This agreement delivers for WHA a relationship that will open channels and distribution networks into China, the world's largest market for nutritional dairy products.

The company lodges its Appendix 4C - Quarterly Report.

The company's AGM will be held at the offices of K&L Gates, Level 25, South Tower, 525 Collins Street, Melbourne, Victoria on Wednesday 27 November 2019 commencing at 11.00am.

The securities of Wattle Health Australia Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of WHA, pending the release of an announcement regarding an update in connection with the proposed acquisition.

The suspension of trading in the securities of Wattle Health Australia Limited will be lifted from the commencement of trading on Tuesday, 2 July 2019, following the release by WHA of an announcement.

The company signs revised debt facility term sheet to increase proposed net cash funding up to US$85 million with Gramercy Funds Management LLC on behalf of its managed vehicles and funds. WHA is also negotiating to increase its shareholding interest in Blend & Pack to 93.5%. B&P is the largest independent (by volume) CNCA certified manufacturing facility in Australia. As an accredited manufacturer under China's CNCA, B&P allows WHA a critical distribution channel into a market where a burgeoning middle class is driving demand for clean, green, Australian nutritional dairy products. WHA will be the sole funder for CBDG for the construction of Australia's first dedicated organic nutritional spray dryer. Upon completion of the acquisition, WHA will be one of the first fully vertically integrated organic nutritional dairy companies in Australia. Uganic nutritional dairy range begins production in August 2019.

The company releases a notice of EGM. The EGM will seek approval for a change to the scale/nature of activities. The meeting wil be held at the offices of K&L Gates, Level 30, North Tower, 525 Collins Street, Melbourne, Victoria on Wednesday 31 July 2019 commencing at 10am.

The securities of Wattle Health Australia Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of WHA, pending the release of an announcement regarding an acquisition and financing proposal.

The suspension of trading in the securities of Wattle Health Australia Limited will be lifted immediately, following the release of an announcement concerning a new debt facility

The company signs US$75 million debt facility term sheet with Gramercy Funds Management LLC, on behalf of its managed vehicles and funds. WHA has entered into an agreement with Mason Group Holdings Limited to acquire 75% of Blend and Pack (B&P) for US$55 million taking its holding to 80%. "¢ B&P is the largest independent (by volume) CNCA certified manufacturing facility in Australia. As an accredited manufacturer under China's CNCA, B&P allows WHA a critical distribution channel into a market where a burgeoning middle class is driving demand for clean, green, Australian nutritional dairy products. Upon completion of the acquisition, WHA will be one of the first fully vertically integrated organic nutritional dairy company in Australia.

The company requests an extension of the voluntary suspension of its securities in order for it to manage its continuous disclosure obligations as it expects to make a material announcement in relation to the proposed transaction. The voluntary suspension is expected to remain in place until the earlier of the commencement of trading on 10 May 2019 or when the announcement is released.

The securities of Wattle Health Australia Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of WHA, pending the release of an announcement.

The suspension of trading in the securities of Wattle Health Australia Limited will be lifted immediately, following the release by the Company of announcements regarding a conditional funding package to meet required commitments for the Corio Bay Dairy Group Joint Venture.

The company releases the chairman's letter regarding the joint venture with Organic Dairy Farmers of Australia.

The company releases an Investor Presentation.

The company issues a prospectus for a non-renounceable pro-rata rights issue to Eligible Shareholders of up to 30,286,785 New Shares on the basis of 1 New Share for every 5 Shares held by Shareholders at the Record Date at an issue price of $1.25 per New Share to raise approximately $37.9 million before costs.

The company has finalised terms for a $77.9 million funding package to meet required commitments for the Corio Bay Dairy Group Joint Venture. Funding comprises a $20.0 million Loan facility, $37.9 million Entitlement Offer and $20.0 million Institutional Placement conditional on raising a minimum of $30.0 million through the Entitlement Offer. CBDG JV is a transformational transaction and will see WHA become one of a few nutritional dairy companies to have access to vertical integration, from the farm to consumer.

Since the entry into the CBDG joint venture, WHA has conducted an institutional roadshow with the intention to structure a capital raising which provides sufficient commitments to fund WHA's obligations under the CBDG joint venture and also gives existing WHA shareholders an ability to participate in any such WHA capital raising. WHA is in ongoing discussions with institutional investors regarding the capital raising and will inform the market on further developments shortly.

The company lodges its Quarterly Activities and Cashflow Statement.

The company requests that the voluntary suspension of its securities continue in place until the earlier release of an ASX announcement in relation to the joint venture agreements with Organic Dairy Farmers of Australia and a potential capital raise or 7 May 2018.

Wattle Health Australia enters into joint venture with Organic Dairy Farmers of Australia and Niche Dairy Pty Ltd to design, construct and operate a dedicated Organic Spray Drying Facility in Australia. Under the joint venture, Wattle Health Australia will have a 45% ownership interest with ODFA a 50% ownership interest and Niche Dairy a 5% ownership interest, to form Corio Bay Dairy Group Pty Ltd

The securities of Wattle Health Australia Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of the Company, pending the release of an announcement regarding the finalisation of a joint venture and/or potential capital raise.

The securities of Wattle Health Australia Limited will be reinstated to official quotation immediately, following the release of an announcement by the Company in relation to its capital raising.

The company successfully closes commitments from institutions and sophisticated investors. The placement was significantly oversubscribed, with the total bids received being in excess of $20 million. Mason Resources Finance have notified Wattle Health Australia their option to subscribe for $500,000 in WHA shares will also be exercised. Wattle Health Australia has notified Mason Resources Finance that the loan agreement with WHA is to be terminated.

The company lodges its Appendix 4C - quarterly report.

The securities of Wattle Health Australia Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement regarding a proposed capital raising.

The securities of Wattle Health Australia Limited will be reinstated to quotation immediately, following the release of an announcement by the Company.

The company has entered into a conditional agreement to acquire a 5% equity interest in the Australian infant formula and nutritional products manufacturer, Blend and Pack.

The securities of Wattle Health Australia Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement regarding a proposed acquisition.

listed entity carried for record purposes only